

Recognized by Medical Council of India /National Medical Commission, Ministry of Health & Family Welfare, Govt. of India Affiliated to Kaloji Narayanarao University of Health Sciences, Warangal, Telangana.

DVV Clarification

3.1.3 Number of research projects/clinical trials funded by government, industries and nongovernmental agencies during the last five years

S.no	Year	Name of the Principal Investigator	Title of the Project	Name of the funding agency	Link
1.	2022-2023	Dr. Pradeep Reddy	A phase III randomised, modified double blinded, multi centric comparartive study to evaluate the non-interiority of immunogenicity & safety of single strain oral cholera vaccine Hillchol (BBV131) to the comparator vaccine Shanchol along with lot to lot consistency of Hillchol (Safety study)	Bharat Biotech International Limited	<u>View</u> Document
2.	2022-2023	Dr. Subhash Reddy	A multicentric, randomised, double blind, placebo controlled study to evaluate the safety & efficacy of Apremilast topical gel, 2%w/w in adult patients with mild to moderate plague psoriasis : Phase III clinical trial	Aizant drug research solutions private limited	<u>View</u> Document
3.	2022-2023	Dr.Suma Priya	A Prospective, Multi-center, Single- arm, Phase IV Study to Assess the Safety and Efficacy of Amoxycillin and Potassium Clavulanate Oral Suspension in Children With Upper Respiratory Tract Infection (URTI) or Lower Respiratory Tract Infection (LRTI). (ICR/22/010)"	Sun pharma laboratories Ltd	<u>View</u> Document

MALLA REDDY MEDICAL COLLEGE FOR WOMEN

Recognized by Medical Council of India /National Medical Commission, Ministry of Health & Family Welfare, Govt. of India

Affiliated to Kaloji Narayanarao University of Health Sciences, Warangal, Telangana.

		Affiliated to Kaloji Narayanarao University of	riculti sciences, we	arangai, relanguna.
2022-2023	Dr.Suma Priya	A phase III randomised, modified double blinded, multi centric comparartive study to evaluate the non-interiority of immunogenicity & safety of single strain oral	Bharat Biotech International Limited	<u>View</u> Document
2021-2022	Dr.Leelabati Toppo	A phase 2 randomised, multicentrric, clinical trial of heterologus Prime- Boost Combination of SARS CoV-2 Vaccines to evaulate the immunogenicity & safety of BBV152(COVAXIN) with BBV154 (Adeno Intranasal COVID 19 VACCINE) in healthy volunteers Protocol Number:BBIL-BBV152/154-2021	Bharat Biotech International Limited	<u>View</u> Document
2021-2022	Dr.K.Praveen	A Phase 2,Randomized,Double blind,Placebo- controlled,Two-arm study to evaluate the efficacy and safety of Hydroxyprogesterone Caproate Intramuscular Injection Plus Dexamethasone compared to Dexamethasone alone in patients with moderate COVID- 19 disease(Non- intubated,Nonmechanical ventilation)Protocol Number:HPC-EG- 009A-2.2	CBCC Global research	<u>View</u> Document
2021-2022	Dr.Ram Prahlad	A Multicentric, Open-label, Randomized, Two Period, Two Treatment, Two Sequence, Crossover, Multiple Dose, Steady state Bioequivalence Study of Sunitinib Malate Capsules 50mg of Eugia Pharma Specialities Limited (A Joint venture of Aurobindo Pharma Limited &Celon Laboratories Limited), India (Test) with Sutent® (Sunitinib Malate) capsules 50 mg ofPfizer Labs, USA (Reference) in adult patients with advanced renal cell carcinoma alreadyreceiving stable dose of Sunitinib Malate Capsules 50 mg under fasting	Clinsync Clinical Research Pvt. Ltd	<u>View</u> Document
	2021-2022 2021-2022	2021-2022 Dr.Leelabati Toppo 2021-2022 Dr.K.Praveen 2021-2022	2022-2023Dr.Suma PriyaA phase III randomised, modified double blinded, multi centric comparative study to evaluate the non-interiority of immunogenicity & safety of single strain oral2021-2022Dr.Leelabati ToppoA phase 2 randomised, multicentrric, clinical trial of heterologus Prime- Boost Combination of SARS CoV-2 Vaccines to evaulate the immunogenicity & safety of BBV152(COVAXIN) with BBV154 (Adeno Intranasal COVID 19 VACCINE) in healthy volunteers Protocol Number:BBIL-BBV152/154-20212021-2022A Phase 2,Randomized,Double blind,Placebo- controlled,Two-arm study to evaluate the efficacy and safety of Hydroxyprogesterone Caproate Intranuscular Injection Plus Dexamethasone alone in patients with moderate COVID- 19 disease(Non- intubated,Nonmechanical ventilation)Protocol Number:HPC-EG- 009A-2.22021-2022Dr.Ram PrahladA Multicentric, Open-label, Randomized, Two Period, Two Sequence,Crossover, Multiple Dose, Steady state Bioequivalence Study of Sunitinib Malate Capsules 50mg of Eugia Pharma Specialities Limited (A Joint venture of Aurobindo Pharma Limited &Celon Laboratories Limited), India (Test) with Sutent@ (Sunitinib Malate) capsules 50 mg ofPrizer Labs, USA (Reference) in adult patients with advanced renal cell carcinoma alreadyreceiving stable dose of Sunitinib	2022-2023 Dr.Suma Priya A phase III randomised, modified double blinded, multi centric comparative study to evaluate the non-interiority of immunogenicity & safety of single strain oral Bharat Biotech International Limited 2021-2022 Dr.Leelabati Toppo A phase 2 randomised, multicentric, clinical trial of heterologus Prime-Boost Combination of SARS CoV-2 Vaccines to evaulate the immunogenicity & safety of BBV152(COVAXIN) with BBV154 (Adeno Intranasal COVID 19 VACCINE) in healthy volunteers Protocol Number:BBIL-BBV152/154-2021 Bharat Biotech International Limited 2021-2022 A Phase 2, Randomized, Double blind, Placebo- controlled, Two-arm study to evaluate the efficacy and safety of Hydroxyprogesterone Caproate Intramuscular Injection Plus Dexamethasone compared to Dexamethasone alone in patients with moderate COVID-19 disease(Non-intubated,Nonmechanical ventilation)Protocol Number:HPC-EG-009A-2:2 CBCC Global research 2021-2022 A Multicentric, Open-label, Randomized, Two Period, Two Treatment, Two Sequence, Crossover, Multiple Dose, Steady state Bioequivalence Study of Sunitinib Malate Capsules 50mg of Eugla Pharma Specialities Limited (A Joint venture of Aurobindo Pharma Limited & Celon Laboratories Limited), India (Test) with Sutent® (Sunitinib Malate); capsules 50 mg under fasting Clinixync Clinixal Research Pvt. Litd Mate Capsules 50 mg under fasting Malte Capsules 50 mg under fasting Malte Capsules 50 mg under fasting

MALLA[®] REDDY MEDICAL COLLEGE FOR WOMEN Recognized by Medical Council of India /National Medical Commission, Ministry of Health & Family Welfare, Govt. of India Affiliated to Kaloji Narayanarao University of Health Sciences, Warangal, Telangana.

			Affiliated to Kaloji Narayanarao University of	Health Sciences, Wa	arangai, leiangana.
8.	2021-2022	Dr.Leelabati Toppo	'A Phase 2, Dose-Ranging, Multicenter, Randomized,Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of AQCH Tablets in Adult Patients with Dengue Fever'Protocol No.: ICR/20/002;	Sun pharma laboratories Ltd	<u>View</u> Document
9.	2021-2022	Dr.Leelabati Toppo	A Phase III randomized open label multi-center study to compare immunogenicity and safety of BBV154 with COVAXIN®, and to assess Lot to Lot Consistency of BBV154 in Healthy Volunteers.Protocol No: BBIL/BBV154-III/2022	Bharat Biotech International Limited	<u>View</u> Document
10.	2020-2021	Dr. N Srinivas Rao	A phase III, randomised, multi- centre, double blind, placebo controlled, study, to evaluate efficay, safety & immunogenicity of Novel Corona Virus - 2019-Ncov vaccine candidate of M's Cadila Healthcare Limited	ZYDUS LIFESCIENCES LIMITED	<u>View</u> Document
11.	2020-2021	Dr.Ajmera Prakash	A Prospective, Multicenter, Randomized, Comparative, Parallel Group Clinical Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety of Intravenous Injection of Tenecteplase(Hetero Biopharma Limited) and Reference Medicinal Product (RMP Tenecteplase, Boehringer Ingelheim) in Adults for the Thrombolytic Treatment of Suspected Myocardial Infarction with Persistent ST Elevation.Protocol ID: HCR/III/TENESTEMI/08/2020	Hetero	<u>View</u> Document
12.	2020-2021	Dr.Ajmera Prakash	Ultra Thin strUt versus XiencE in a diabetic population with multi-Vessel Diseases -2- India study (TUXEDO - 2 INDIA)	Batra Hospital and medical research centre	<u>View</u> Document



Recognized by Medical Council of India /National Medical Commission, Ministry of Health & Family Welfare, Govt. of India Affiliated to Kaloji Narayanarao University of Health Sciences, Warangal, Telangana.

					0
13.	2020-2021	Dr.Archana	A Phase 2, Randomized, Double	CBCC Global	View
		Andhavarapu	blind,Placebo-controlled study on	research	Document
			the safety and efficacy of		
			Niclosamide in patients with		
			COVID-19 with Gastrointestinal		
			infection		
			Protocol Number:AZ-NICL-COV-1		
14.	2020-2021	Dr.Archana	A Phase III,	Cadila	<u>View</u>
		Andhavarapu	Randomized,Controlled,Open-Label	Healthcare	Document
			study to evaluate the efficacy and	Limited	
			safety of Pegylated Interferon Alfa-		
			2b in the treatment of adult		
			patients diagnosed with		
			SARS-Cov-2 (COVID-19)Protocol		
			Number:PEGI.20.005		